News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

InVivo Therapeutics Corporation, Geisinger Health System to Conduct Preclinical Study of Injectable Scaffold for Peripheral Nerve Injury for FDA Submission



1/17/2012 6:43:51 AM

CAMBRIDGE, Mass. & DANVILLE, Pa.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI), and Geisinger Health System today announced a research collaboration to conduct a preclinical study using InVivo’s injectable biocompatible hydrogel for the treatment of chronic pain caused by peripheral nerve compression. InVivo expects to submit data from the study to the U.S. Food and Drug Administration (FDA) in 2012 representing the Company’s first technology to treat degenerative neurologic conditions outside of the spinal cord.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES